Posted by Michael Wonder on 02 Apr 2025
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A (final guidance)
2 April 2025 - NICE has published final evidence-based recommendations on the use of efanesoctocog alfa (Altuvoct) for the treatment and prevention of bleeding episodes in patients with haemophilia A.
Efanesoctocog alfa is recommended as an option for the treatment and prevention of bleeding episodes in patients 2 years of age and over with haemophilia A only if they have a factor VIII activity level of less than 1% (severe haemophilia A
Efanesoctocog alfa is recommended only if Sobi provides it according to the commercial arrangement
